About Bruce

A successful pharmaceutical executive with nearly 35 years of industry experience, Bruce Eaton serves as the president and chief executive officer of i2 Pharmaceuticals, Inc. In his leadership role with i2 Pharmaceuticals, he looks to expand the company‚Äôs intellectual property holdings, which include a broad range of early and late stage pharmaceutical assets. Through a… Continue Reading

FDA OKs Checkpoint Inhibitors for New Cancers – What You Need to Know

FDA OKs Checkpoint Inhibitors for New Cancers – What You Need to Know

Some of the most successful approaches to immuno-oncology have dealt with inhibition of the immune checkpoints expressed on cancer cells. These immune checkpoint inhibitor drugs include Keytruda and Opdivo, two of the most popular immunotherapies on the market. Keytruda has been approved as a treatment for metastatic melanoma and non-small cell lung cancer, as well… Continue Reading

Spotlight – The Struggle to Find a Cancer Vaccine Continues

Spotlight – The Struggle to Find a Cancer Vaccine Continues

With the exception of the HPV vaccine, which is a preventative rather than a therapeutic vaccine, most attempts at formulating a cancer vaccine have fallen flat. Most of the earliest cancer vaccines focused on bolstering the immune system to protect against cancer growth in the body. Sometimes, these vaccines did invoke a strong immune response,… Continue Reading

Immune Activation Advances Hold Promise for Immuno-Oncology

Immune Activation Advances Hold Promise for Immuno-Oncology

Immuno-oncology has largely changed the landscape of cancer care, but a number of challenges still exist. From judging efficacy to understanding why some people react to the treatment while others do not, researchers are tackling a number of issues. One young startup in Europe is attempting to address the latter question. At present, only about… Continue Reading